4 recruiting, 1 active not recruiting, 1 suspended, 1 terminated. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Suspended 1 |
| Phase 2 | 3 | Recruiting 2, Terminated 1 |
Follow iadademstat: new trials by email Literature Review of iadademstat trials Research Report on iadademstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Iadademstat + SBRT With Atezo in ES-SCLC Iadademstat, Atezolizumab, SBRT - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Recruiting | Yale University | 15 | 2026-01-20 | 2026-09-14 |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-10-27 |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2025-04-08 | 2026-09-17 |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 1 | Suspended | National Cancer Institute (NCI) | 45 | 2024-12-18 | 2026-08-25 |
| Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia Azacitidine, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia, Myelodysplastic Syndrome/Acute Myeloid Leukemia | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 30 | 2024-08-22 | 2026-06-30 |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET Iadademstat, Paclitaxel - Small-cell Lung Cancer, Neuroendocrine Carcinoma | Phase 2 | Terminated | Fox Chase Cancer Center | 20 | 2022-12-21 | 2025-07-30 |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Iadademstat, Gilteritinib Oral Tablet - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1 | Active not recruiting | Oryzon Genomics S.A. | 50 | 2022-11-14 | 2026-08-24 |
Leukemia, Myeloid, Acute (3) · Carcinoma, Neuroendocrine (1) · GATA2 Deficiency (1) · Lung Neoplasms (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Myeloproliferative Disorders (1) · Polycythemia Vera (1) · Primary Myelofibrosis (1) · Recurrence (1) · Small Cell Lung Carcinoma (1) · Thrombocythemia, Essential (1)
National Cancer Institute (NCI) (3) · Fox Chase Cancer Center (1) · OHSU Knight Cancer Institute (1) · Oryzon Genomics S.A. (1) · Yale University (1)
United States (7)
Anand A Patel (1) · Annie Chiang, MD (1) · Annie P Im (1) · Charles M Rudin (1) · Curtis A Lachowiez (1) · Namrata Vijavergia (1)
UM1CA186690 (1), UM1CA186691 (1), UM1CA186717 (1)